Bibliometric analysis of metformin as an immunomodulator (2013–2024)

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 8, 2025

Metformin, the frontline treatment for diabetes, has considerable potential as an immunomodulator; however, detailed bibliometric analyses on this subject are limited. This study extracted 640 relevant articles from Web of Science (WOS) Core Collection and conducted visual using Microsoft Excel, VOSviewer, CiteSpace. The findings showed that research immunomodulatory function metformin grown steadily since 2017, with China United States being leading contributors. These studies have mostly been published in journals such International Journal Molecular Sciences, Cancers, Frontiers Immunology, Scientific Reports. Keyword co-occurrence analysis highlighted metformin's role immunomodulator, particularly context tumor immune microenvironment, immunosuppressive checkpoints, derivatives. Recent application aging, autoimmune diseases, COVID-19, tuberculosis. Additionally, its regulating inflammation gut microbiota is also investigated. Overall, effects were investigated anti-tumor, antiviral, anti-aging, disease research. highlights scope use these fields, while significantly enhancing clinical value a repurposed drug.

Language: Английский

Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

We report a case of poorly differentiated pancreatic cancer that showed an exceptional response to combination therapy with nivolumab and metformin. A 58-year-old man presented epigastric pain was diagnosed locally advanced para-aortic lymph node metastasis. After disease progression following modified FOLFIRINOX (a fluorouracil, leucovorin, irinotecan, oxaliplatin), the patient enrolled in phase Ib clinical trial (3 mg/kg biweekly) combined metformin (750 mg/day). Post-treatment imaging marked tumor shrinkage normalization markers. During treatment, early-stage lung underwent successful left S1+S2 segmentectomy temporary suspension immunotherapy. The therapeutic has been sustained for seven years, minimal residual disease. This unprecedented duration is particularly noteworthy considering his microsatellite stability, which typically predicts limited immune checkpoint inhibition. demonstrates cancer. remarkable durability suggests need further investigation identify patients most likely benefit from this approach.

Language: Английский

Anti-Diabetic Therapies and Cancer: From Bench to Bedside

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1479 - 1479

Published: Nov. 20, 2024

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.

Language: Английский